China's drug development explosion forces a US biotech reckoning
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers. Shortly after, they did what many researchers do when...
View ArticleWhat to make of UnitedHealth Group’s rebate move
In its first earnings since the murder of UnitedHealthcare CEO Brian Thompson, UnitedHealth Group made a move that caught industry insiders’ attention. The healthcare giant said its pharmacy benefit...
View ArticleSanofi says no supply interruptions after landing FDA warning letter for US site
A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in Massachusetts. The letter, published on Tuesday, was handed to Sanofi on ...
View ArticleJ&J's Spravato wins expanded label for depression as singular treatment
Johnson & Johnson’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive disorder in adults after two oral antidepressants fail,...
View ArticleRenewed mifepristone fight will test Trump’s abortion stance
A revived legal challenge to the abortion pill mifepristone will be an early test for President Donald Trump’s administration and his appetite for further weighing in on reproductive health access in...
View ArticleUS withdrawal from WHO could jeopardize information sharing
The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health information that’s vital for pharmaceutical companies, academics said Tuesday....
View ArticleOncology biotech ArriVent does another China ADC deal, this time with Lepu...
Bing Yao's ArriVent BioPharma has inked another licensing deal with a Chinese biopharma. The late-stage oncology biotech is picking up a new antibody-drug conjugate from Shanghai-based Lepu Biopharma,...
View ArticleGLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?
A new study found that patients taking GLP-1s to treat type 2 diabetes have a lower risk of developing Alzheimer’s disease, potentially opening the door to another lucrative category for Novo Nordisk....
View ArticleRegeneron CSO George Yancopoulos on AI's hype and potential
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine. Agreeing to put $3 billion toward ...
View ArticleInhibrx’s early colorectal cancer data clouded by patient death
One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is under scrutiny after a patient enrolled in the Phase 1 trial died. The...
View ArticleJ&J’s Spravato hit $1B in revenue in 2024
Johnson & Johnson’s burgeoning depression treatment Spravato eclipsed $1 billion in revenue in 2024 as the pharma’s neuroscience pipeline comes into view. In its fourth-quarter earnings on...
View ArticleShanghai Bao, Sichuan Biokin file IPOs in Hong Kong; Disc's $200M offering
Plus, news about Rivus and Crown Labs: Two Chinese biotechs file for stock listings in Hong Kong: Shanghai Bao Pharmaceuticals and Sichuan Biokin Pharmaceutical join a queue of Chinese drug developers...
View ArticleXilio reports handful of responses for combo in colorectal cancer
Xilio Therapeutics said its anti-CTLA-4 produced promising initial data in certain colorectal cancer patients enrolled in a mid-stage trial. But the drug’s future is uncertain as the company grapples...
View ArticleRFK Jr. says he’ll divest interests in CRISPR Therapeutics if confirmed for...
HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR Therapeutics and Dragonfly Therapeutics, if confirmed by the Senate, he said in a...
View ArticleUpdated: Biogen enacts layoffs across its research unit
Biogen is laying off staff across its research unit, marking one of the most concerted strategic decisions from Jane Grogan since she took over the department. A company spokesperson said in a...
View ArticleHealth navigation company Quantum Health lays off 4% of workforce
Longtime digital health company Quantum Health has laid off workers days after it appointed a new CEO, Endpoints News has learned. Founded in 1999, private equity-backed Quantum provides services for...
View ArticleSamsung Biologics hits revenue high, secures largest contract to date
Samsung Biologics closed 2024 on several high notes, reaching its highest annual revenue to date — and just a week ago, securing its largest client contract so far. Samsung Bio pulled in a record-high...
View ArticleChinese startup begins first clinical trial using CRISPR to edit cells...
A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive races. YolTech Therapeutics announced Monday that it started a clinical trial...
View ArticleJ&J reinforces Caplyta blockbuster projections, won't shelve neuro prospects
Johnson & Johnson made the largest splash at this year’s JP Morgan Healthcare Conference, acquiring Intra-Cellular Therapies and its neuropsychiatric drug Caplyta for $14.6 billion. On the...
View Article